Paper 27 - SAFETY AND EFFICACY UPDATES FROM A PHASE 1 STUDY OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

Author(s)

• 

  Hans Gelderblom, MD, PhD (he/him/his)

  Medical Oncologist
  Leiden University Medical Center
  Leiden, Zuid-Holland, Netherlands

  Slides

Co-Author(s)

• AA

  Albiruni Ryan Abdul Razak, MB BCh, BM BCh

  Princess Margaret Cancer Center
  Toronto, Ontario, Canada
• JM

  Javier Martin-Broto, MD, PhD (he/him/his)

  Medical oncology
  Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
  Madrid, Madrid, Spain
• BW

  Breelyn A. Wilky, MD

  University of Colorado Cancer Center
  Aurora, Colorado, United States
• 

  Piotr Rutkowski, MD, PhD

  Head of Department of Soft Tissue/Bone Sarcoma and Melanoma
  Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
  Warsaw, Mazowieckie, Poland
• NB

  Nicholas Bernthal, MD

  University of California Los Angeles
  Los Angeles, California, United States
• 

  Supraja Narasimhan, MS, PhD

  Associate Director, Clinical Scientist
  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• MS

  Maitreyi G. Sharma, MD (she/her/hers)

  VP, Late Clinical Development
  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• RR

  Rodrigo Ruiz-Soto, MD/MSc (he/him/his)

  Sr. Vice President Clinical Development
  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• MS

  Matthew L. Sherman, MD

  Deciphera Pharmaceuticals, LLC
  Waltham, Massachusetts, United States
• WT

  William D. Tap, MD

  Chief, Sarcoma Medical Oncology
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States